Zobrazeno 1 - 10
of 15
pro vyhledávání: '"Carol Farhangfar"'
Autor:
Joel R. Eisner, Kirk D. Beebe, Gregory M. Mayhew, Yoichiro Shibata, Yuelong Guo, Carol Farhangfar, Farhang Farhangfar, Joshua M. Uronis, Jill Mooney, Michael V. Milburn, David Foureau, Richard L. White, Asim Amin, Marcos E. Milla
Publikováno v:
Cancer Research Communications. 2:894-903
Recombinant human high-dose IL2 (HD-IL2; aldesleukin) was one of the first approved immune-oncology agents based upon clinical activity in renal cell carcinoma (RCC) and metastatic melanoma but use was limited due to severe toxicity. Next-generation
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::3af86004040503294c91ba86fa069a5e
https://doi.org/10.1158/2767-9764.crc-21-0153
https://doi.org/10.1158/2767-9764.crc-21-0153
Autor:
Joel R. Eisner, Gregory M. Mayhew, James M. Davison, Kirk D. Beebe, Yoichiro Shibata, Yuelong Guo, Carol Farhangfar, Farhang Farhangfar, Joshua M. Uronis, Jeffrey M. Conroy, Michael V. Milburn, David Neil. Hayes, Kathryn F. Mileham
Publikováno v:
Clinical Cancer Research.
Purpose: The Piedmont study is a prospectively designed retrospective evaluation of a new 48-gene antifolate response signature (AF-PRS) in patients with locally advanced/metastatic NS-NSCLC treated with pemetrexed-containing platinum doublet chemoth
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::43c4953b0bb03f5b73d0ac32e56d115c
https://doi.org/10.1158/1078-0432.ccr-22-2558
https://doi.org/10.1158/1078-0432.ccr-22-2558
Autor:
Marcos E. Milla, Asim Amin, Richard L. White, David Foureau, Michael V. Milburn, Jill Mooney, Joshua M. Uronis, Farhang Farhangfar, Carol Farhangfar, Yuelong Guo, Yoichiro Shibata, Gregory M. Mayhew, Kirk D. Beebe, Joel R. Eisner
Recombinant human high-dose IL2 (HD-IL2; aldesleukin) was one of the first approved immune-oncology agents based upon clinical activity in renal cell carcinoma (RCC) and metastatic melanoma but use was limited due to severe toxicity. Next-generation
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::0aee2f498634f181e0903dde0904d827
https://doi.org/10.1158/2767-9764.c.6550872.v1
https://doi.org/10.1158/2767-9764.c.6550872.v1
Autor:
Marcos E. Milla, Asim Amin, Richard L. White, David Foureau, Michael V. Milburn, Jill Mooney, Joshua M. Uronis, Farhang Farhangfar, Carol Farhangfar, Yuelong Guo, Yoichiro Shibata, Gregory M. Mayhew, Kirk D. Beebe, Joel R. Eisner
this is a test
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::0dcd889514c515c62aa335b1a1f130c0
https://doi.org/10.1158/2767-9764.22545183
https://doi.org/10.1158/2767-9764.22545183
Autor:
Marcos E. Milla, Asim Amin, Richard L. White, David Foureau, Michael V. Milburn, Jill Mooney, Joshua M. Uronis, Farhang Farhangfar, Carol Farhangfar, Yuelong Guo, Yoichiro Shibata, Gregory M. Mayhew, Kirk D. Beebe, Joel R. Eisner
40 gene IL-2 response classifier and related immune cell types
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::5e912be1d5a6174fc4d7074ca2edfe78
https://doi.org/10.1158/2767-9764.22545180
https://doi.org/10.1158/2767-9764.22545180
Autor:
Ivanina Foureau, Anna V.1 (AUTHOR) anna.ivanina@atriumhealth.org, Foureau, David M.2 (AUTHOR) david.foureau@atriumhealth.org, McHale, Cody C.3 (AUTHOR) cody.mchale@atriumhealth.org, Guo, Fei2 (AUTHOR) fei.guo@atriumhealth.org, Farhangfar, Carol J.1 (AUTHOR), Mileham, Kathryn F.4 (AUTHOR) anna.ivanina@atriumhealth.org
Publikováno v:
Cancers. Jul2024, Vol. 16 Issue 13, p2475. 21p.
Publikováno v:
Oncology Nursing Forum. Mar2017, Vol. 44 Issue 2, special section p1-215. 215p.
Autor:
Foureau, David, Amin, Asim, White, Richard, Anderson, William, Jones, Chase, Sarantou, Terry, McKillop, Iain, Salo, Jonathan
Publikováno v:
Cancer Immunology, Immunotherapy; Dec2014, Vol. 63 Issue 12, p1329-1340, 12p
Autor:
Chad A. Livasy, Derek Raghavan, David Arguello, Zoran Gatalica, Nury Steuerwald, Peter E. Clark, Earle F. Burgess, James T. Symanowski, Carol J. Farhangfar, Claud Grigg
Publikováno v:
Clinical Cancer Research. 26:B03-B03
Background: Small-cell bladder cancer (SCBC) is a rare histologic subtype that confers a poor prognosis and lacks predictive biomarkers. Because mutations in the PTEN/AKT pathway are important in urothelial tumor biology, we sought to characterize PT
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::1e5de1d8e8e8d0ff96c0eb45df6c34d6
https://doi.org/10.1158/1557-3265.bladder19-b03
https://doi.org/10.1158/1557-3265.bladder19-b03
Autor:
Blackley, Kris, Morris, Victoria, Raghavan, Derek, Kowalkowski, Marc, Farhangfar, Carol, Green, John, Plate, Kevin
Publikováno v:
Journal of Oncology Navigation & Survivorship; Oct2016, Vol. 7 Issue 9, p32-33, 2p